Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies

BACKGROUND: Trials of disease-modifying therapies (DMTs) for multiple sclerosis (MS) often include patients with minimal disability. Patient-reported outcome instruments used in these trials have often not captured physical and psychological treatment effects concomitant with observed clinical benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Regnault, Antoine, Loubert, Angely, Brennan, Róisín, Meunier, Juliette, Naujoks, Christel, Cano, Stefan, Adlard, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540592/
https://www.ncbi.nlm.nih.gov/pubmed/37780483
http://dx.doi.org/10.1177/20552173231201422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540592/
https://www.ncbi.nlm.nih.gov/pubmed/37780483
http://dx.doi.org/10.1177/20552173231201422

Ejemplares similares